Zoetis (ZTS) Q3 2026 Earnings Call Transcript

Zoetis reported Q3 2026 revenue of $2.4 billion, down 1% organically, while adjusted diluted EPS rose 1% to $1.75; companion animal revenue fell 5% amid competition and softer clinic visits, partly offset by 7% livestock growth and 13% diagnostics growth. The company narrowed full-year revenue guidance to $9.22 billion-$9.32 billion, implying an organic decline of 2%-1%, and raised adjusted diluted EPS guidance to $6.25-$6.35. Management said it is not assuming improved macro conditions or pet-owner spending in 2027, and expects competitive pressures to persist; Zoetis returned $2.4 billion through repurchases and dividends in the first nine months of 2026.

Analysis

The key signal is not simply weak companion-animal demand: Zoetis is spending gross-to-net to slow share loss, and management has not shown that this defense can restore growth without a lasting margin cost. The sequential improvement in U.S. dermatology share loss is encouraging but remains a leading indicator, not proof of a revenue inflection; two stable quarters are management’s own practical test. Meanwhile, buybacks lifted adjusted EPS despite weaker adjusted net income, so EPS resilience overstates operating momentum and should not be capitalized as evidence of recovery.

Near term, Q4’s expected sequential step-down is partly promotion timing, so avoid treating it as a clean demand signal. Over the next 1–3 months, watch Q4 disclosure for share stabilization, gross-to-net intensity, and 2027 guidance assumptions. Cytopoint long-acting and other launches are more credible catalysts for 2027–28 than for 2027 earnings; launch execution and uptake remain unverified. Livestock diversifies the downside, but recent growth includes specific market/product drivers and is exposed to disease, weather, and production cycles. Diagnostics growth also needs to be separated into acquired contribution versus underlying utilization.

Contrarian read: a sharp selloff could over-discount a temporary competitive reset if promotions stabilize share and pipeline launches expand treatment adoption. Conversely, the market may underweight how long promotions and affordability pressure can suppress margins and category growth. Without valuation and post-call price data, there is no basis for a price target or asserting the reaction is overdone.

Key Decisions for Investors

• Keep ZTS at neutral/underweight rather than add on EPS growth alone. Reassess after Q4 results and 2027 guidance; require evidence of two consecutive quarters of stable or improving dermatology share alongside moderation in gross-to-net investment before turning constructive.
• Do not read the expected Q4 sequential revenue decline as an independent short catalyst: promotions shifted sales timing between quarters. The more informative bear signal is continued share loss together with further operational gross-margin compression.
• Treat Cytopoint long-acting and the 2027 launch slate as watch items, not near-term earnings estimates. Upgrade the catalyst case only on approval, launch timing, and early adoption evidence; the thesis is weakened if launch contribution remains delayed into 2028.
• Monitor livestock growth quality and diagnostics’ organic contribution. A reversal in international livestock demand or evidence that diagnostics growth is predominantly acquisition-led would reduce the portfolio’s offset to companion-animal weakness.